67 related articles for article (PubMed ID: 23318440)
1. The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.
Munugalavadla V; Mariathasan S; Slaga D; Du C; Berry L; Del Rosario G; Yan Y; Boe M; Sun L; Friedman LS; Chesi M; Leif Bergsagel P; Ebens A
Oncogene; 2014 Jan; 33(3):316-25. PubMed ID: 23318440
[TBL] [Abstract][Full Text] [Related]
2. Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells.
Wang B; Lyu H; Pei S; Song D; Ni J; Liu B
Cell Cycle; 2018; 17(8):985-996. PubMed ID: 29969371
[TBL] [Abstract][Full Text] [Related]
3. Phosphatidylinositide 3-kinase (PI3K) and PI3K-related kinase (PIKK) activity contributes to radioresistance in thyroid carcinomas.
Burrows N; Williams J; Telfer BA; Resch J; Valentine HR; Fitzmaurice RJ; Eustace A; Irlam J; Rowling EJ; Hoang-Vu C; West CM; Brabant G; Williams KJ
Oncotarget; 2016 Sep; 7(39):63106-63123. PubMed ID: 27527858
[TBL] [Abstract][Full Text] [Related]
4. The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition.
Craveiro RB; Ehrhardt M; Velz J; Olschewski M; Goetz B; Pietsch T; Dilloo D
Oncotarget; 2017 Jul; 8(29):46915-46927. PubMed ID: 28159923
[TBL] [Abstract][Full Text] [Related]
5. A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells.
Singh AV; Bandi M; Raje N; Richardson P; Palladino MA; Chauhan D; Anderson KC
Blood; 2011 May; 117(21):5692-700. PubMed ID: 21454451
[TBL] [Abstract][Full Text] [Related]
6. SUMOylation inhibition enhances dexamethasone sensitivity in multiple myeloma.
Du L; Liu W; Aldana-Masangkay G; Pozhitkov A; Pichiorri F; Chen Y; Rosen ST
J Exp Clin Cancer Res; 2022 Jan; 41(1):8. PubMed ID: 34983615
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of anti-PIK3CG treatment for multiple myeloma via inhibiting c-Myc pathway.
Di X; Pan Y; Yan J; Liu J; Wen D; Jiang H; Zhang S
Heliyon; 2024 Jan; 10(1):e23165. PubMed ID: 38163179
[TBL] [Abstract][Full Text] [Related]
8. The Selective SIRT3 Inhibitor 3-TYP Represses Primary Myeloma Growth by Reducing c-Myc Stability.
Zeng Y; Zhang Y; Cui Z; Mao J; Xu J; Yao R
Chem Res Toxicol; 2024 May; ():. PubMed ID: 38815162
[TBL] [Abstract][Full Text] [Related]
9. Correction: Mannino et al. Beta-Caryophyllene Exhibits Anti-Proliferative Effects through Apoptosis Induction and Cell Cycle Modulation in Multiple Myeloma Cells.
Mannino F; Pallio G; Corsaro R; Minutoli L; Altavilla D; Vermiglio G; Allegra A; Eid AH; Bitto A; Squadrito F; Irrera N
Cancers (Basel); 2023 Nov; 15(21):. PubMed ID: 37958482
[TBL] [Abstract][Full Text] [Related]
10. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.
Sarker D; Ang JE; Baird R; Kristeleit R; Shah K; Moreno V; Clarke PA; Raynaud FI; Levy G; Ware JA; Mazina K; Lin R; Wu J; Fredrickson J; Spoerke JM; Lackner MR; Yan Y; Friedman LS; Kaye SB; Derynck MK; Workman P; de Bono JS
Clin Cancer Res; 2015 Jan; 21(1):77-86. PubMed ID: 25370471
[TBL] [Abstract][Full Text] [Related]
11. Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.
Burger JA; Okkenhaug K
Nat Rev Clin Oncol; 2014 Apr; 11(4):184-6. PubMed ID: 24642682
[TBL] [Abstract][Full Text] [Related]
12. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.
Garcia PD; Langowski JL; Wang Y; Chen M; Castillo J; Fanton C; Ison M; Zavorotinskaya T; Dai Y; Lu J; Niu XH; Basham S; Chan J; Yu J; Doyle M; Feucht P; Warne R; Narberes J; Tsang T; Fritsch C; Kauffmann A; Pfister E; Drueckes P; Trappe J; Wilson C; Han W; Lan J; Nishiguchi G; Lindvall M; Bellamacina C; Aycinena JA; Zang R; Holash J; Burger MT
Clin Cancer Res; 2014 Apr; 20(7):1834-45. PubMed ID: 24474669
[TBL] [Abstract][Full Text] [Related]
13. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.
O'Brien NA; McDonald K; Tong L; von Euw E; Kalous O; Conklin D; Hurvitz SA; di Tomaso E; Schnell C; Linnartz R; Finn RS; Hirawat S; Slamon DJ
Clin Cancer Res; 2014 Jul; 20(13):3507-20. PubMed ID: 24879796
[TBL] [Abstract][Full Text] [Related]
14. Targeting drug-resistant prostate cancer with dual PI3K/mTOR inhibition.
Tang KD; Ling MT
Curr Med Chem; 2014; 21(26):3048-56. PubMed ID: 24735368
[TBL] [Abstract][Full Text] [Related]
15. The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice.
Haagensen EJ; Thomas HD; Wilson I; Harnor SJ; Payne SL; Rennison T; Smith KM; Maxwell RJ; Newell DR
PLoS One; 2013; 8(12):e81763. PubMed ID: 24339963
[TBL] [Abstract][Full Text] [Related]
16. PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models.
Winkler DG; Faia KL; DiNitto JP; Ali JA; White KF; Brophy EE; Pink MM; Proctor JL; Lussier J; Martin CM; Hoyt JG; Tillotson B; Murphy EL; Lim AR; Thomas BD; Macdougall JR; Ren P; Liu Y; Li LS; Jessen KA; Fritz CC; Dunbar JL; Porter JR; Rommel C; Palombella VJ; Changelian PS; Kutok JL
Chem Biol; 2013 Nov; 20(11):1364-74. PubMed ID: 24211136
[TBL] [Abstract][Full Text] [Related]
17. Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and -γ.
Chandrasekaran S; Funk CR; Kleber T; Paulos CM; Shanmugam M; Waller EK
Front Immunol; 2021; 12():718621. PubMed ID: 34512641
[TBL] [Abstract][Full Text] [Related]
18. Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.
Ippen FM; Grosch JK; Subramanian M; Kuter BM; Liederer BM; Plise EG; Mora JL; Nayyar N; Schmidt SP; Giobbie-Hurder A; Martinez-Lage M; Carter SL; Cahill DP; Wakimoto H; Brastianos PK
Neuro Oncol; 2019 Nov; 21(11):1401-1411. PubMed ID: 31173106
[TBL] [Abstract][Full Text] [Related]
19. The ion channel TRPV5 regulates B-cell signaling and activation.
Mahtani T; Sheth H; Smith LK; Benedict L; Brecier A; Ghasemlou N; Treanor B
Front Immunol; 2024; 15():1386719. PubMed ID: 38694510
[TBL] [Abstract][Full Text] [Related]
20. The discrete roles of individual FOXO transcription factor family members in B-cell malignancies.
Lees J; Hay J; Moles MW; Michie AM
Front Immunol; 2023; 14():1179101. PubMed ID: 37275916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
